Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents.
Although second-generation antipsychotics (SGAs) are used increasingly in children and adolescents, data on the effectiveness and safety in pediatric populations are still sparse. Much of the safety information is derived from studies conducted in adults. This derivation is problematic because children and adolescents are exposed to SGAs during a phase of unparalleled physical and psychologic development that can affect pharmacokinetic and pharmacodynamic drug actions, efficacy, and side-effect patterns. This article presents an overview of SGA-related side effects in children and adolescents and strategies to monitor health outcomes effectively in youngsters receiving SGAs.
Correll
Christoph U
CU
The Zucker Hillside Hospital, North Shore-Long Island Jewish Health System, 75-59 263rd Street, Glen Oaks, NY 11004, USA. ccorrell@lij.edu
Penzner
Julie B
JB
Parikh
Umesh H
UH
Mughal
Tahir
T
Javed
Tariq
T
Carbon
Maren
M
Malhotra
Anil K
AK
D000293:Adolescent; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D015992:Body Mass Index; D002648:Child; D050171:Dyslipidemias / Q000139:chemically induced; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy*; D024821:Metabolic Syndrome / Q000139:chemically induced; D011388:Prolactin / Q000378:metabolism; D021641:Recognition, Psychology
D014150:Antipsychotic Agents; D011388:Prolactin